| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5703017 | GILEAD | 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation |
Dec, 2014
(9 years ago) | |
| US7601730 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(8 years ago) | |
| US7109205 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(8 years ago) | |
| US8349843 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(8 years ago) | |
| US5840722 | GILEAD | Use of carboxylic acid derivatives as drugs |
Nov, 2015
(8 years ago) | |
| USRE42462 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Jul, 2018
(5 years ago) | |
| US9474752 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(3 years from now) | |
| US8377933 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(3 years from now) | |
| US9549926 | GILEAD | Compositions and methods of treating pulmonary hypertension |
Oct, 2031
(7 years from now) | |
Letairis is owned by Gilead.
Letairis contains Ambrisentan.
Letairis has a total of 9 drug patents out of which 6 drug patents have expired.
Expired drug patents of Letairis are:
- US5703017
- US7601730
- US7109205
- US8349843
- US5840722
- USRE42462
Letairis was authorised for market use on 15 June, 2007.
Letairis is available in tablet;oral dosage forms.
Letairis can be used as treatment of pulmonary arterial hypertension by inhibiting endothelin receptors, for the treatment of pulmonary hypertension (pah) in combination with tadalafil, for the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3, method to treat pulmonary hypertension by administering ambrisentan to a patient.
Drug patent challenges can be filed against Letairis from 16 June, 2011.
The generics of Letairis are possible to be released after 14 October, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2012 |
| New Indication(I-716) | Oct 02, 2018 |
| Orphan Drug Exclusivity(ODE) | Jun 15, 2014 |
Drugs and Companies using AMBRISENTAN ingredient
NCE-1 date: 16 June, 2011
Market Authorisation Date: 15 June, 2007
Treatment: Method to treat pulmonary hypertension by administering ambrisentan to a patient; Treatment of pulmonary arterial hypertension by inhibiting endothelin receptors; For the treatment of pulmonary hypert...
Dosage: TABLET;ORAL
LETAIRIS family patents
